FOLH1 and neoplasm: PSMA-RLT eligibility in prostate cancer is assessed through PSMA PET/CT imaging, with an eligibility cutoff tumor/liver ratio > 1.5 in [68 Ga]Ga-PSMA PET/CT according to the EANM guideline [22].